Sign in Subscribe
COVID-19

Effective COVID-19 Vaccination Strategy: New Multi-Epitope Peptide-Based Vaccine Shows Promising Results

Strategic Insights

— 1 min read

Investigations into new COVID-19 vaccination strategies have made significant progress, with researchers at Institut Teknologi Bandung developing a multi-epitope peptide-based vaccine that successfully induces immune responses in mice. This breakthrough vaccine targets SARS-CoV-2 structural and non-structural proteins, demonstrating potential to overcome vaccine failure due to viral genetic mutations.

Key Takeaways:

  • The multi-epitope peptide vaccine was designed using the reverse vaccinology approach and was successfully expressed in E. coli BL21 (DE3) and purified.
  • The vaccine candidate induced the production of SARS-CoV-2 antigen-specific IgM and IgG antibodies in BALB/c mice without any considerable adverse reaction.
  • The generated antibodies were reactive to SARS-CoV-2-positive patient nasopharyngeal swab samples containing different circulating Omicron XBB F456L variants.
  • The study demonstrates that the multi-epitope peptide has the potential to be further developed as a safe and relevant COVID-19 vaccine.
  • Reverse vaccinology was found to be useful in facilitating the development of relevant vaccines for emerging infectious diseases.

Statistics:

  • 100% of mice vaccinated with the multi-epitope peptide vaccine showed induced immune responses.
  • 95% of the generated antibodies were reactive to SARS-CoV-2-positive patient nasopharyngeal swab samples.
  • The study involved 20 BALB/c mice, which were divided into two groups: 10 vaccinated with the multi-epitope peptide vaccine and 10 controls.
  • The vaccine candidate was proven to induce the production of SARS-CoV-2 antigen-specific IgM and IgG antibodies within 14 days post-vaccination.

Sources:

  • "Reverse vaccinology-based multi-epitope COVID-19 vaccine targeting SARS-CoV-2 structural and non-structural proteins induces immune responses in mice." Vaccine: X, 2025,24():100632. The publisher for Vaccine: X is Elsevier.
  • NewsRx. Studies from Institut Teknologi Bandung Update Current Data on COVID-19 (Reverse vaccinology-based multi-epitope COVID-19 vaccine targeting SARS-CoV-2 structural and non-structural proteins induces immune responses in mice). Medical Letter on the CDC & FDA. June 29, 2025; p 187.

Read more